Citigroup Inc Biomarin Pharmaceutical Inc Put Options Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $883,456 - $1.2 Million	-12,800 Reduced 42.67%	17,200 $1.21 Million
Q2 2024 Aug 12, 2024	BUY	$74.43 - $92.22 $2.23 Million - $2.77 Million	30,000 New	30,000 $2.47 Million
Q2 2023 Aug 10, 2023	BUY	$86.68 - $100.3 $433,400 - $501,500	5,000 Added 16.67%	35,000 $3.03 Million
Q1 2023 May 11, 2023	BUY	$87.74 - $117.27 $877,400 - $1.17 Million	10,000 Added 50.0%	30,000 $2.92 Million
Q4 2022 Feb 09, 2023	SELL	$80.93 - $108.63 $809,300 - $1.09 Million	-10,000 Reduced 33.33%	20,000 $2.07 Million
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $821,600 - $969,400	-10,000 Reduced 25.0%	30,000 $2.54 Million
Q2 2022 Aug 10, 2022	BUY	$71.48 - $86.85 $2.86 Million - $3.47 Million	40,000 New	40,000 $3.32 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.